4
Changes in Ownership
Keros Therapeutics, Inc. Filed Acc 0001209191-22-023037
Chief Operating Officer sold 864 shares at an average $57.49 ($49,675)
- Chief Operating Officer acquired 864 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Option exercise | +864 | $16.00 | $13,824 | 864 | D: show line 1 in the form |
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Sale | −2 | $54.34 | $109 | 862 | D: show line 2 in the form |
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Sale | −104 | $56.20 | $5,845 | 758 | D: show line 3 in the form |
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Sale | −287 | $56.89 | $16,327 | 471 | D: show line 4 in the form |
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Sale | −366 | $57.97 | $21,217 | 105 | D: show line 5 in the form |
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Sale | −105 | $58.83 | $6,177 | 0 | D: show line 6 in the form |
| Open-market sales · 864 sh · avg $57.49 · $49,675 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Rovaldi Christopher Chief Operating Officer | 2022-04-01 | Option exercise · Employee Stock Option (right to buy) | −864 | 9,730 | D: show line 7 in the form |
Loading xslF345X03/doc4.xml…